drugset / Trial / NCT07313761
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
Timeline
- Start
- 2025-12-15
- Primary completion
- 2026-06-26
- Completion
- 2026-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maridebart Cafraglutide | Unknown | — | Subcutaneous |
Indications
No indication recorded.